Depreciation of Krystal Biotech, Inc. from 30 Sep 2016 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Krystal Biotech, Inc. quarterly and annual Depreciation in USD history and change rate from 30 Sep 2016 to 31 Dec 2025.
  • Krystal Biotech, Inc. Depreciation for the quarter ending 31 Dec 2025 was $1,614,000, a 12% increase year-over-year.
  • Krystal Biotech, Inc. Depreciation for the twelve months ending 31 Dec 2025 was $5,724,000, a 4.1% decline year-over-year.
  • Krystal Biotech, Inc. annual Depreciation for 2025 was $5,724,000, a 4.1% decline from 2024.
  • Krystal Biotech, Inc. annual Depreciation for 2024 was $5,967,000, a 19% increase from 2023.
  • Krystal Biotech, Inc. annual Depreciation for 2023 was $5,007,000, a 89% increase from 2022.
Source SEC data
View on sec.gov
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Change (%)
Depreciation, Annual (USD)
Depreciation, YoY Annual Change (%)

Krystal Biotech, Inc. Quarterly Depreciation (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $5,724,000 $1,614,000 +$174,000 +12% 01 Oct 2025 31 Dec 2025 10-K 17 Feb 2026 2025 FY
Q3 2025 $5,550,000 $1,400,000 +$100,000 +7.7% 01 Jul 2025 30 Sep 2025 10-Q 03 Nov 2025 2025 Q3
Q2 2025 $5,450,000 $1,300,000 -$500,000 -28% 01 Apr 2025 30 Jun 2025 10-Q 04 Aug 2025 2025 Q2
Q1 2025 $5,950,000 $1,410,000 -$17,000 -1.2% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $5,967,000 $1,440,000 -$74,000 -4.9% 01 Oct 2024 31 Dec 2024 10-K 17 Feb 2026 2025 FY
Q3 2024 $6,041,000 $1,300,000 +$100,000 +8.3% 01 Jul 2024 30 Sep 2024 10-Q 03 Nov 2025 2025 Q3
Q2 2024 $5,941,000 $1,800,000 +$600,000 +50% 01 Apr 2024 30 Jun 2024 10-Q 04 Aug 2025 2025 Q2
Q1 2024 $5,341,000 $1,427,000 +$334,000 +31% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 $5,007,000 $1,514,000 +$496,000 +49% 01 Oct 2023 31 Dec 2023 10-K 17 Feb 2026 2025 FY
Q3 2023 $4,511,000 $1,200,000 +$531,000 +79% 01 Jul 2023 30 Sep 2023 10-Q 04 Nov 2024 2024 Q3
Q2 2023 $3,980,000 $1,200,000 +$706,000 +143% 01 Apr 2023 30 Jun 2023 10-Q 05 Aug 2024 2024 Q2
Q1 2023 $3,274,000 $1,093,000 +$631,000 +137% 01 Jan 2023 31 Mar 2023 10-Q 06 May 2024 2024 Q1
Q4 2022 $2,643,000 $1,018,000 +$556,000 +120% 01 Oct 2022 31 Dec 2022 10-K 19 Feb 2025 2024 FY
Q3 2022 $2,087,000 $669,000 +$195,000 +41% 01 Jul 2022 30 Sep 2022 10-Q 06 Nov 2023 2023 Q3
Q2 2022 $1,892,000 $494,000 +$19,000 +4% 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023 2023 Q1
Q1 2022 $1,873,000 $462,000 +$24,000 +5.5% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023 2023 Q1
Q4 2021 $1,849,000 $462,000 +$90,000 +24% 01 Oct 2021 31 Dec 2021 10-K 26 Feb 2024 2023 FY
Q3 2021 $1,759,000 $474,000 +$75,000 +19% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022 2022 Q3
Q2 2021 $1,684,000 $475,000 +$81,000 +21% 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2022 Q2
Q1 2021 $1,603,000 $438,000 +$103,000 +31% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q4 2020 $1,500,000 $372,000 +$121,000 +48% 01 Oct 2020 31 Dec 2020 10-K 27 Feb 2023 2021 FY
Q3 2020 $1,379,000 $399,000 +$209,000 +110% 01 Jul 2020 30 Sep 2020 10-Q 08 Nov 2021 2021 Q3
Q2 2020 $1,170,000 $394,000 +$219,000 +125% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q2
Q1 2020 $951,000 $335,000 +$203,000 +154% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q4 2019 $748,000 $251,000 +$189,000 +305% 01 Oct 2019 31 Dec 2019 10-K 01 Mar 2021 2020 FY
Q3 2019 $559,000 $190,000 +$152,000 +400% 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020 2020 Q3
Q2 2019 $407,000 $175,000 +$152,000 +661% 01 Apr 2019 30 Jun 2019 10-Q 07 Aug 2020 2020 Q2
Q1 2019 $255,000 $132,000 +$114,000 +633% 01 Jan 2019 31 Mar 2019 10-Q 04 May 2020 2020 Q1
Q4 2018 $141,000 $62,000 +$48,000 +343% 01 Oct 2018 31 Dec 2018 10-K 10 Mar 2020 2019 FY
Q3 2018 $93,000 $38,000 +$33,000 +660% 01 Jul 2018 30 Sep 2018 10-Q 04 Nov 2019 2019 Q3
Q2 2018 $60,000 $23,000 +$20,000 +667% 01 Apr 2018 30 Jun 2018 10-Q 05 Aug 2019 2019 Q2
Q1 2018 $40,000 $18,000 +$17,000 +1700% 01 Jan 2018 31 Mar 2018 10-Q 07 May 2019 2019 Q1
Q4 2017 $23,000 $14,000 01 Oct 2017 31 Dec 2017 10-K 12 Mar 2018 2017 FY
Q3 2017 $5,000 +$5,000 01 Jul 2017 30 Sep 2017 10-Q 05 Nov 2018 2018 Q3
Q2 2017 $3,000 01 Apr 2017 30 Jun 2017 10-Q 06 Aug 2018 2018 Q2
Q1 2017 $1,000 01 Jan 2017 31 Mar 2017 10-Q 07 May 2018 2018 Q1
Q3 2016 $0 01 Jul 2016 30 Sep 2016 10-Q 13 Nov 2017 2017 Q3

Krystal Biotech, Inc. Annual Depreciation (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $5,724,000 -$243,000 -4.1% 01 Jan 2025 31 Dec 2025 10-K 17 Feb 2026 2025 FY
2024 $5,967,000 +$960,000 +19% 01 Jan 2024 31 Dec 2024 10-K 17 Feb 2026 2025 FY
2023 $5,007,000 +$2,364,000 +89% 01 Jan 2023 31 Dec 2023 10-K 17 Feb 2026 2025 FY
2022 $2,643,000 +$794,000 +43% 01 Jan 2022 31 Dec 2022 10-K 19 Feb 2025 2024 FY
2021 $1,849,000 +$349,000 +23% 01 Jan 2021 31 Dec 2021 10-K 26 Feb 2024 2023 FY
2020 $1,500,000 +$752,000 +101% 01 Jan 2020 31 Dec 2020 10-K 27 Feb 2023 2021 FY
2019 $748,000 +$607,000 +430% 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2021 2020 FY
2018 $141,000 +$118,000 +513% 01 Jan 2018 31 Dec 2018 10-K 10 Mar 2020 2019 FY
2017 $23,000 +$21,000 +1050% 01 Jan 2017 31 Dec 2017 10-K 12 Mar 2018 2017 FY
2016 $2,000 01 Jan 2016 31 Dec 2016 10-K 12 Mar 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.